Horizon Pharma’s Ravitchi (Glycerol Phenylbutyrate) Receives FDA Approval for Expansion of Age Range for in Patients with Urea Cycle Disorder (UCD)

 Horizon Pharma’s Ravitchi (Glycerol Phenylbutyrate) Receives FDA Approval for Expansion of Age Range for in Patients with Urea Cycle Disorder (UCD)

Horizon Pharma’s Ravitchi (Glycerol Phenylbutyrate) Receives FDA Approval for Expansion of Age Range for in Patients with Urea Cycle Disorder (UCD)

Shots:
  • The expansion approval of age range for ravicti is based on the study assessing safety, efficacy and PK in UCD infants patients aged ≤ 2mos.
  • The study demonstrated safety and efficacy in children younger than two months, with stable ammonia levels relative to pre-study enrollment
  • Ravitchi (glycerol phenylbutyrate) is an oral nitrogen binding agent liquid, indicated for chronic management of patients with urea cycle disorders (UCDs)

 Click here to read full press release/ article | Ref: Horizon Pharma | Image: WMA Consulting Engineers

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post